Intrathecal transplantation of human umbilical cord mesenchymal stem cells enhances spinal cord injury recovery: Role of miR‑124‑3p as a biomarker

This study explores a new way to treat spinal cord injuries (SCI) using human umbilical cord mesenchymal stem cells (hUCMSCs). These cells have shown promise in helping nerves regenerate and controlling the body's immune response. The study also looks at a molecule called miR-124-3p, which might be a useful marker for tracking how well the spinal cord is healing. By transplanting hUCMSCs into rats with SCI, the researchers aimed to see if it could improve their condition. The findings suggest that hUCMSC transplantation can indeed enhance recovery from SCI, likely by promoting the growth of new nerve cells and influencing miR-124-3p expression.

• 1
  hUCMSC transplantation improved motor function in rats with SCI, particularly on days 7 and 14 post-injury, as measured by the BBB locomotor rating scale and Rivlin inclined plane test.
• 2
  Histological analysis showed that hUCMSC transplantation reduced scar tissue formation and increased neuron survival in the injured spinal cord.
• 3
  The expression of BDNF, a neurorepair-related protein, was significantly higher in the hUCMSC group compared to the control group, suggesting enhanced neuroregeneration.